Cardiac troponin I in healthy Norwegian Forest Cat,Birman and domestic shorthair cats,and in cats with hypertrophic cardiomyopathy

Abstract

Objectives

The aims of this study were to assess the potential associations between the serum cardiac troponin I (cTnI) concentration in healthy cats and feline characteristics, systolic blood pressure, heart rate (HR), echocardiographic measurements and storage time; and to compare cTnI concentrations in healthy cats with concentrations in cats with hypertrophic cardiomyopathy (HCM), with or without left atrial enlargement (LAE) and in cats with HCM, to assess potential associations between cTnI concentration and echocardiographic variables.

Methods

Cardiac TnI was analysed using an Abbott ARCHITECT ci16200 analyser in serum from prospectively included healthy Norwegian Forest Cat (NF; n = 33), Birman (n = 33) and domestic shorthair (DSH; n = 30) cats, and from 39 cats with HCM, with or without LAE.

Results

In healthy cats, higher cTnI concentrations were found in Birman cats than in NF cats (P = 0.014) and in neutered male cats than in intact females (P = 0.032). Cardiac TnI was positively associated with HR (P <0.0001). In cats with HCM, cTnI concentration was positively associated with left ventricular wall thickness and with left atrial-to-aortic root ratio (all P ⩽0.010). Cats with HCM had higher cTnI concentrations than healthy cats, and cTnI concentrations were higher in cats with HCM and LAE than in those with HCM without LAE (all P = 0.0003).

Conclusions and relevance

Breed and sex may affect serum cTnI concentrations in healthy cats. The cTnI concentration increased with increasing severity of HCM.

Keywords

hs-cTnI breed biomarker feline heart

Introduction

Cardiac troponin I (cTnI) is a sensitive biomarker for myocardial injury, and high-sensitivity cTnI (hs-cTnI) assays allow detection of low concentrations of cTnI in healthy cats,^1–4 dogs^1,5 and humans.⁶ An hs-cTnI assay enables the detection of cTnI concentrations in >50% of healthy humans, with a coefficient of variation (CV) of ⩽10% for the 99th percentile.⁶ In humans, different cut-off values are used for the available hs-cTnI assays because of varying capture and detection antibodies and lack of standardisation.^7,8 Only one hs-cTnI assay has been validated in cats.¹ In humans, male sex is positively associated with cTnI concentration, and sex-specific reference intervals (RIs) are used.^9–11 Breed differences have been found in healthy dogs,^12,13 and a previous report in cats with hypertrophic cardiomyopathy (HCM) indicated a breed effect.¹⁴ In healthy cats, cTnI concentrations have neither been associated with sex nor with breed or body condition score (BCS).^2,3,14 Results in cats regarding associations between cTnI concentrations and age and body weight (BW) are conflicting.^2,3,15

HCM is a common cardiac disease in cats, with a reported prevalence rate of approximately 15%.^16,17 The disease is characterised by left ventricular hypertrophy in the absence of other explanations for wall thickening,¹⁸ and may lead to congestive heart failure (CHF), arterial thromboembolism (ATE), arrhythmia or sudden death.^19–21 Using conventional cTnI assays, significantly higher concentrations have been detected in cats with HCM than in healthy cats,^22,23 in which cTnI concentrations have been reported to be commonly below the detection limit.^23,24 In cats with HCM, positive associations between cTnI concentrations and hypertrophy of the left ventricle (LV), and with left atrial enlargement (LAE), have been shown.^2–4,23 Although cTnI is specific for the myocardium, increased cTnI concentrations are not specific for primary cardiac disease but have also been shown in cats with hyperthyroidism,²⁵ hypertension,²⁶ renal disease²⁷ and critical illness.²⁸

The aims of this study were to assess potential associations between serum concentration of cTnI in healthy cats and feline characteristics (breed, sex, age, BW and BCS), systolic blood pressure (SBP), heart rate (HR) at auscultation, echocardiographic measurements and storage time. A further aim was to compare cTnI concentrations in healthy cats with concentrations in cats with HCM, with and without LAE, and in cats with HCM, to assess potential associations between serum cTnI concentration in cats with HCM and echocardiographic variables. We hypothesised that the serum concentration of cTnI in healthy cats may be influenced by feline characteristics, and that cTnI concentrations may differ between healthy cats and cats with HCM, with or without LAE.

Materials and methods

This prospective observational study was approved by the Uppsala Animal Experiment Ethics Board, Sweden (C137/13). Client-owned cats were recruited through information distributed online, at seminars or at recruiting clinics. Cats were examined at the Evidensia Animal Clinic in Västerås, Sweden, between September 2014 and June 2017. Clinically healthy cats and cats with murmurs or previously diagnosed HCM were examined for possible inclusion. Informed written consent was obtained from the owner of each cat. The population has, in part, been described previously.^29,30

Inclusion criteria

Apparently healthy Norwegian Forest Cat (NF), Birman and domestic shorthair (DSH) cats aged 1–14 years, with normal echocardiograms, were included, as were cats of any breed with preclinical HCM or clinical HCM stabilised following CHF therapy. A diagnosis of HCM was based on characteristic findings on an echocardiogram, as outlined below.

Exclusion criteria

Cats with mean SBP >160 mmHg, or increased serum concentrations of total thyroxine (TT4), creatinine or alanine aminotransferase were excluded. Cats with decompensated CHF, ATE, congenital cardiac disease, other acquired cardiovascular disorders, equivocal findings concerning the presence of LV hypertrophy, or significant organ-related or systemic diseases other than HCM were excluded. All cats receiving medical treatment other than standard CHF treatment, standard antithrombotic treatment or medroxyprogesterone acetate were excluded.

Physical examination and blood pressure measurements

All examinations were performed according to a standardised protocol in a quiet examination room by an experienced veterinarian (SH). SBP was measured indirectly using a high-definition oscillometric device (VET Memodiagnostic HDO monitor; S+B medVET),³¹ followed by a general physical examination, including assessment of BCS on a nine-point scale,³² echocardiography and blood sampling for haematology, biochemistry profiles, and TT4 and fructosamine levels, as previously described.²⁹

Echocardiography

Echocardiographic examination was performed using an ultrasound unit (IE33; Philips Ultrasound) equipped with a 4–12 MHz phased-array probe, and with continuous electrocardiogram monitoring.³³ The left atrial-to-aortic root diameter ratio (LA:Ao) was measured from the right two-dimensional short-axis view.³⁴ Left atrial enlargement was defined as LA:Ao ⩾1.5.³⁵ End-diastolic and systolic LV dimensions (interventricular septum in diastole [IVSd], LV internal diameter in diastole [LVIDd], LV free wall in diastole [LVFWd] and LV internal diameter in systole [LVIDs]) were measured from M-mode and two-dimensional images, and fractional shortening (FS) was calculated.^33,36

A diagnosis of HCM was made when subjective impression of hypertrophy (diffuse or regional) with a non-dilated LV chamber was supported by increased M-mode and two-dimensional diastolic LV wall dimensions of the IVSd, LVFWd or both, as previously described.²⁹ Expected BW-dependent values for the IVSd, LVIDd and LVFWd, as well as percentage deviations from these expected values, were calculated for both healthy cats and cats with HCM according to previously generated formulas for cats.³⁵ The calculated deviations and LA:Ao were used to classify cats into three groups – healthy controls, HCM without LAE and HCM with LAE – as described previously.²⁹

Analytical performance of hs-cTnI

The validation study was set up in accordance with the Clinical and Laboratory Standards Institute document EP15-A3, evaluating precision using a one-way ANOVA.³⁷ In the imprecision study, two concentrations of pooled feline serum (cTnI concentrations 22.8 ng/l and 312.7 ng/l, respectively) and two human control samples (Liquicheck Cardiac Marker LT1 and Liquicheck Cardiac Marker Cardio 2 [Bio-Rad Laboratories]) were used. Each sample was analysed three times daily for 5 days to determine within-run (CV_R), between-run (CV_B) and within-laboratory (CV_WL) repeatability. Limit of blank (LOB) was evaluated using 20 replicates of physiological saline solution. Linearity under dilution was performed in duplicate through the dilution of two concentrations of pooled feline serum (45 ng/l and 173 ng/l, respectively) with physiological saline solution as serial dilution and the addition of an extra sample consisting of 75% feline serum and 25% physiological saline solution. Recovery ([observed/expected concentration] × 100) was calculated. Stability was determined by keeping fresh feline serum samples with initial cTnI concentrations of 1070, 1040, 761 and 91 ng/l, respectively, at 20°C in the dark for 0, 3, 5 and 7 days, respectively, and then stored at −80°C until thawed for batched analysis. The effect of freezing and thawing was determined by assaying aliquots of fresh feline serum samples subjected to three cycles of freezing at −80°C for 24 h and thawing to room temperature for 30 mins.

Analysis of cTnI in cats

Whole blood was centrifuged and the serum stored at −80°C within 60 mins of collection. Samples were transported from the clinic to the laboratory at −80°C using a portable freezer. Serum for cTnI was batch-analysed in duplicate at an accredited laboratory at the Department of Clinical Chemistry and Pharmacology, Uppsala University Hospital, using a two-step, double-monoclonal chemiluminescent microparticle immunoassay for the detection of cTnI concentration (Abbott ARCHITECT ci16200 analyser; Abbott Laboratories). The reported assay interval for cTnI concentration was 2–50,000 ng/l. Concentrations <2 ng/l were assigned a value of 2 ng/l in the calculations.

Statistical analysis

Statistical analyses were performed using Rstudio³⁸ and JMP (version 12.2.0; SAS Institute). A P value <0.05 was considered to be statistically significant. Descriptive statistics for continuous variables (age, BW, SBP, HR, basic echocardiographic measurements and basic laboratory variables) were presented as mean ± SD. Within each of these continuous variables, multiple comparisons were performed between breeds for healthy cats, and between healthy cats and cats with HCM, using one-way ANOVA followed by Tukey’s honestly significant difference (HSD) test.

Data on cTnI concentrations were presented as median and interquartile range (IQR). Potential associations between cTnI concentration in healthy cats, as well as in cats with HCM and the variables breed, sex, BCS, age, BW, SBP, HR, echocardiographic measurements IVSd_inc%, LVIDd_inc%, LVFWd_inc%, FS% and LA/Ao, and the duration of storage at −80°C of serum samples, were analysed using univariable linear regression for continuous variables and one-way ANOVA for categorical variables. BCS was divided into normal (BCS 4–5) and overweight (BCS 6–7), and sex into four classes (male, female, neutered male and neutered female). Variables with a P value <0.2 were included in a linear multiple regression analysis and, as cTnI is a marker of myocardial injury, a variable for the LV wall – LVPWd_inc% – was also included in the model for healthy cats. A model selection was performed, excluding covariate echocardiographic variables for the LV, using the echocardiographic variable with the lowest P value in the model. The variable with the highest P value was then removed until all remaining variables had a P value <0.05. The model with the lowest Akaike information criterion was chosen. All variables were assessed as main effects. The interactions breed × BW and breed × sex were evaluated but were not significant and thus not included in the model. All multiple regression analyses were performed after logarithmic transformation of cTnI concentrations, to have normally distributed residuals. For multiple comparisons between sex and breed categories, respectively, Tukey’s HSD test was used as implemented by the routine general linear hypotheses in the R package ‘multcomp’.

Comparisons of cTnI concentrations between the healthy, HCM without LAE and HCM with LAE groups were done using the Kruskal–Wallis test, followed by post-hoc Wilcoxon tests for each pair.

Results

Validation of the hs-cTnI immunoassay

The CV_R, CV_B and CV_WL were 4.0–8.6% for the feline samples and 5.1–8.4% for the human control samples. Assay results were adequately linear after dilution and the recovery was 64–116%. The LOB was 0.25 ± 0.12 ng/l. After 3 days of storage at room temperature, the concentrations of cTnI were still within 10% in comparison with the initial values (see Supplementary Appendix 1 and Supplementary Figure 1 in the supplementary material).

Study population

Healthy cats

The 96 healthy cats comprised Birman, NF and DSH cats. The characteristics of the healthy cats are presented in Table 1 and their basic echocardiographic data in Supplementary Table 1; excluded cats are detailed in Figure 1.

Table 1

Feline characteristics, heart rate (HR) at auscultation and systolic blood pressure (SBP) in 96 healthy cats

Group	Birman (n = 33)	DSH (n = 30)	NF (n = 33)
Sex
Female	12	0	10
Male	5	0	3
Female neutered	9	14	12
Male neutered	7	16	8
Age (years)	4.8 ± 4.0^a	7.0 ± 4.4^a	5.0 ± 3.0^a
Body weight (kg)	3.6 ± 0.7^a	4.7 ± 1.1^b	5.4 ± 1.6^b
Normal*	21	12	14
Overweight^†	11^‡	18	19
HR (bpm)	159 ± 20^a	151 ± 27^a	165 ± 27^a
SBP (mmHg)	125 ± 11^a	140 ± 10^b	134 ± 13^b

Data are provided mean ± SD for continuous variables. Within each row, values with different superscripts differ significantly between groups. Statistical significance was set at P <0.05. Multiple comparisons within each independent variable were corrected using Tukey’s method

Body condition score (BCS) 4–5/9

†

BCS 6–7/9

‡

One missing value

DSH = domestic shorthair; NF = Norwegian Forest Cat; LAE = left atrial enlargement; HR = heart rate at auscultation; bpm = beats/min; SBP = systolic blood pressure

Figure 1

Flow chart of the study, including the reasons for the exclusion of 30 cats

Cats with HCM

The 39 cats with HCM comprised 18 DSH and cats from 10 different breeds (five Persian, four NF, two Bengal, two Maine Coon, two Ragdoll and one each of the following breeds: British Shorthair, Cornish Rex, Devon Rex, Exotic Shorthair, Siberian and Sphynx). Of 32 cats with HCM without LAE, one female was treated with medroxyprogesterone acetate, and three were treated with enalapril. Of the seven cats with HCM and LAE, three cats with stabilised CHF were treated with furosemide and enalapril, one of which also received clopidogrel. The characteristics of the included cats with HCM are presented in Table 2 and their basic echocardiographic data in Supplementary Table 2; excluded cats are detailed in Figure 1.

Table 2

Feline characteristics, heart rate (HR) at auscultation, systolic blood pressure (SBP) and selected echocardiographic data in 96 healthy cats and 39 cats with hypertrophic cardiomyopathy (HCM)

Group	Healthy (n = 96)	HCM without LAE (n = 32)	HCM with LAE (n = 7)
Sex
Female	22	3	1
Male	8	4	0
Female neutered	35	9	0
Male neutered	31	16	6
Age (years)	5.6 ± 3.9^a	6.1 ± 3.4^a	6.3 ± 2.7^a
Weight (kg)	4.6 ± 1.4^a	5.1 ± 1.2^a	4.8 ± 1.1^a
Normal*	47	6	5
Overweight^†	48^‡	22^§	2
HR (bpm)	158 ± 25^a	167 ± 26^a	169 ± 31^a
SBP (mmHg)	133 ± 13^a	138 ± 12^a	128 ± 11^a
LA:Ao	1.1 ± 0.1^a,¶	1.1 ± 0.1^a,¶	1.6 ± 0.1^b,¶
LVFWd (mm)	3.8 ± 0.5^a,¶	5.4 ± 1.3^b,¶	7.6 ± 0.5^c,¶
LVFWd_inc%	−0.9 ± 9.5^a,¶	39.6 ± 33.2^b,¶	99.8 ± 16.7^c,¶

Mean ± SD is provided for continuous variables. Within each row, values with different superscripts differ significantly between groups. Multiple comparisons within each independent variable were corrected using Tukey’s method. The level of statistical significance was set at P <0.05

Body condition score (BCS) 4–5/9

†

Overweight = BCS 6–7/9

‡

One missing value

Four missing values

Expected differences due to echocardiographic classification of cats into three groups: healthy controls, HCM without LAE, and HCM with LAE

HR = heart rate at auscultation; LAE = left atrial enlargement; bpm = beats/min; SBP = systolic blood pressure; LA:Ao = left atrial-to-aortic root diameter ratio; LVFWd = left ventricular free wall in diastole; LVFWd_inc% = percentage increase left ventricular free wall in diastole

Association between cTnI and feline characteristics, and clinical and echocardiographic variables in healthy cats

cTnI was >2 ng/l in 89/96 samples (93%). cTnI was significantly associated with breed and sex, and positively associated with HR (Tables 3 and 4) but not with age, SBP within the normal range or LVFWd_inc%. Higher cTnI concentrations were found in Birman cats than in NF cats (P = 0.014), and in neutered males than in intact females (P = 0.032; Tables 3 and 4). The final multiple regression model included breed, sex, HR and LVFWd_inc% (Table 4).

Table 3

Serum concentration of cardiac troponin I (cTnI) in 96 healthy cats

Group	n	Median (IQR) cTnI (ng/l)	Range (ng/l)
Breed
NF	33	4.0 (2.6–7.7)^a	<2.0–42.0
Birman	33	7.6 (3.3–14.4)^b	<2.0–49.0
DSH	30	7.7 (3.0–16.1)^a,b	<2.0–156.0
Sex
Intact female	22	3.7 (2.1–7.5)^a	<2.0–20.0
Intact male	8	7.8 (5.5–10.5)^a,b	<2.0–24.0
Female neutered	35	6.3 (3.3–11.5)^a,b	<2.0–156.0
Male neutered	31	7.5 (3.0–16.0)^b	<2.0–61.5
All cats	96	5.7 (2.8–11.0)	<2.0–156.0

Different superscripts within a column denote differences in cTnI concentrations between breed and sex, respectively. The level of statistical significance level was set at P <0.05. Multiple comparisons within breed and sex were adjusted using Tukey’s method

IQR = interquartile range; NF = Norwegian Forest Cat; DSH = domestic shorthair

Table 4

Final model in the multiple regression analysis of association between the effects of feline characteristics and echocardiographic variables and heart rate (HR) at auscultation on the serum concentration of cardiac troponin I (cTnI) in 96 healthy cats

Variable	Estimate	P value	Adjusted P value	95% CI
NF	Baseline breed
Birman	0.589	0.005	0.014	0.133–1.045
DSH	0.521	0.023	0.058	0.080–0.961
Female sex	Baseline sex
Male sex	0.417	0.22	0.599	−0.245 to 1.079
Female neutered	0.483	0.045	0.178	0.017–0.948
Male neutered	0.708	0.0067	0.032	0.209–1.208
HR (bpm)	0.017	<0.0001		0.010–0.024
LVFWd_inc%	0.012	0.19		−0.006 to 0.030

The estimate column gives the estimated regression coefficients in the fitted regression model. cTnI is a marker of myocardial injury, and thus a variable for the left ventricular wall (LVPWd_inc%) was included in the model. The level of statistical significance was set at P <0.05. Multiple comparisons within breed and sex, respectively, were adjusted using Tukey’s method. The final model had an r² of 0.23 and an overall P value of <0.0001

CI = confidence interval; NF = Norwegian Forest Cat; DSH = domestic shorthair; HR = heart rate at auscultation; bpm = beats/min; LVFWd_inc% = percentage increase left ventricular free wall in diastole (percentage)

Association between cTnI and HCM

The median cTnI serum concentration in cats with HCM was 37 ng/l (IQR 17.5–81.5), and was higher in cats with HCM with LAE than in cats with HCM without LAE or in healthy cats (P <0.0001; Table 5). All three groups differed (all P = 0.0003; Table 5). For the analysis of the 39 cats with HCM, the final model included the variables LWFWd_inc% and LA/Ao, both positively associated with cTnI (Table 6).

Table 5

Serum concentration of cardiac troponin I (cTnI) vs echocardiographic classification in the study population of 135 cats

Group	n	Median (IQR) cTnI (ng/l)	Range (ng/l)
Healthy controls	96	5.7 (2.8–11.0)^a	<2.0–156.0
HCM without LAE	32	29.3 (13.3–46.5)^b	3.1–318.0
HCM with LAE	7	296 (92.0–642.0)^c	56.0–1880.0

Different superscripts within a column denote differences in cTnI concentrations between the groups (healthy controls, HCM without LAE and HCM with LAE). The level of statistical significance was set at P <0.05. For multiple comparisons, Kruskal–Wallis test was used, followed by post-hoc Wilcoxon tests for each pair

HCM = hypertrophic cardiomyopathy; LAE = left atrial enlargement; IQR = interquartile range

Table 6

Final model in the multiple regression analysis of association between the effects of echocardiographic variables on the serum concentration of cardiac troponin I in 39 cats with hypertrophic cardiomyopathy

Variable	Estimate	P value	95% CI
LVFWd_inc%	0.016	0.004	0.006–0.026
LA:Ao	2.41	0.010	0.66–4.15

The estimate column gives the estimated regression coefficients in the fitted regression model. The level of statistical significance was set at P <0.05. The final model had an adjusted r² of 0.46 and an overall P value of <0.0001

CI = confidence interval; LA:Ao = left atrial-to-aortic root diameter ratio; LVFWd_inc% = percentage increase of the left ventricular free wall in diastole

Discussion

In the present study, the hs-cTnI assay was precise and accurate for use in cats. The main findings were a significant association between serum cTnI concentrations and breed, sex and HR in healthy cats. There was no significant association between cTnI concentration and age, or with SBP within the normal range. There were significant differences in serum cTnI concentration between healthy cats, cats with HCM without LAE and cats with HCM with LAE, which is in accordance with previous studies in cats.^2,3

In healthy cats, higher cTnI concentrations were found in Birman cats than in NF cats. Interbreed variations have previously been reported in dogs, with higher cTnI concentrations in Greyhound and Boxer dogs than in other breeds,^12,13 but not in healthy cats.^2,3,14 In cats with HCM, a previous study indicated a breed effect with higher cTnI concentrations in British Shorthair cats than in Maine Coons.¹⁴ However, echocardiographic variables indicating the severity of HCM were not included in the statistical analysis in that study,¹⁴ thus the British Shorthair cats may simply have had more severe HCM at inclusion than the Maine Coons. An effect of sex was also found in healthy cats, with higher cTnI concentrations in male neutered cats than in intact female cats. In humans, women have been described as having lower cTnI concentrations than men.^9,39 In the present study, intact female cats had lower concentrations of cTnI than intact males. The observed difference was not statistically significant, but this may have been a type II statistical error due to the small number of intact cats included in the study. Healthy cats had comparatively lower serum cTnI concentrations, and the breed and sex associations were probably detected owing to the more sensitive cTnI assay used in the present study, as compared with previously used assays in cats.^2,3,14 However, despite being statistically significant, differences in cTnI concentrations among breed and sex were much smaller than between healthy cats and cats with HCM, and likely not of relevance in a clinical situation. Further studies would be needed to investigate if breed- and sex-specific RIs are beneficial.

The lack of association between age and cTnI concentration is in contrast to reports on healthy people,^40,41 healthy dogs⁴² and dogs with mild myxomatous mitral valve disease,⁴³ where cTnI has been positively associated with age. In cats, both a positive association¹⁵ and no association^2,3 with age have been previously described. In the present study, the mean age of the healthy cats was 5.6 years, with few older cats, which possibly contributed to the lack of association.

In the present study, a positive association between cTnI concentration and HR was found in healthy cats. Prolonged exercise or stress increases HR and blood pressure.^44–46 In humans⁴⁷ and in horses,^48–50 post-exercise-induced cTnI elevations have been reported after normal physical activity, with a peak at 3–6 h post-exercise and normalisation within 24 h.^49,51 The increase of circulating cTnI after exercise has been suggested to arise from a proportion of cTnI that is free in the cytosol,⁵² and thus not a sign of cardiac damage. In the present study, blood sampling was performed a couple of hours after leaving home, and situational stress might be an explanation for higher HR.

cTnI concentration differed significantly between healthy cats, cats with HCM without LAE and cats with HCM with LAE. Previous investigations in humans,⁵³ cats^4,54 and dogs⁴³ suggest that cTnI correlates with the severity of HCM and myxomatous mitral valve disease. Echocardiography is used for the diagnosis of LV hypertrophy and the HCM phenotype in cats.^18,55–57 Diagnosis is based on a subjective impression of LV hypertrophy supported by measurement of maximal end-diastolic wall thicknesses via two-dimensional or M-mode echocardiography.^58–60 Fixed diagnostic cutoffs defining normal diastolic LV wall thickness have been used.^55,60,61 Several studies have recommended allometric scaling and BW-based 95% prediction intervals, in particular in small and large cats.^35,62,63 In the present study, BW-dependent echocardiographic values, as well as percentage deviations from these expected values, were calculated and used. Evaluations of the cTnI concentration for assessing HCM in cats categorised using echocardiographic measurements adjusted for BW have, to our knowledge, not been published previously. Cats with HCM and LAE have a more severe disease than cats with HCM without LAE.^20,64–66 In a study with a median follow-up of 3.1 years, cats with HCM and LAE were four times more likely to experience a cardiac event than cats with a normal atrial size.⁶⁷ In accordance with previous studies in cats, concentrations of cTnI in cats with HCM were positively associated with LVFWd_inc% and LA:Ao,^2,3 possibly caused by myocardial ischaemia due to myocyte death or by an imbalance between hypertrophy of the myocardium and insufficient coronary arterial supply.^68,69 Although cTnI is heart-specific, increases are not specific for conditions affecting the heart, and increased cTnI concentrations have been described in cats with hyperthyroidism,²⁵ hypertension,²⁶ renal disease²⁷ and critical illness.²⁸

Concentrations of cTnI differ substantially between different hs-cTnI assays,⁷ and concentrations obtained with different hs-cTnI assays are therefore difficult to compare. In the present study, cTnI was detectable in 93% of healthy cats, which is higher than previously reported in cats evaluated using another hs-cTnI assay.² The CVs in our study were comparable to those previously reported for cTnI assays in humans,^70,71 dogs^1,72 and cats.¹ The concentration of cTnI in samples stored at 20°C for 3 days changed by less than 10%, possibly enabling the transport of fresh feline serum samples to a central laboratory. However, stability was only studied for cTnI concentrations above 90 ng/l, and studies of concentrations closer to the clinical cutoff would be valuable. In the present study, cTnI analyses for the healthy cats and the cats with HCM were performed after up to 5 years of serum storage at −80°C, but storage time was not associated with cTnI concentration in the statistical analysis.⁷¹

The design of our study, with different criteria for selection of the healthy controls and the cats with HCM (ie, three specific breeds were included as healthy controls and any breed was permitted in the HCM cat group), is a limitation. The different breed distributions may have affected the results because breed influences the cTnI concentration. Only healthy cats and cats with HCM, but no other known diseases, were included in the study. Cats with equivocal echocardiographic findings and measurements, or other comorbidities were excluded, which introduces the spectrum effect for cTnI concentration.⁷³ In a mixed cat population, including cats with comorbidities, the rate of elevated cTnI results would increase and the accuracy for the test for discriminating healthy cats from cats with HCM is likely to decrease. The present study was intended as an exploratory study, and further research in a mixed cat population is warranted for a discriminatory analysis. Body-weight dependent echocardiographic values were used for both healthy cats and cats with HCM, which affected the ability to compare the results to those of previous studies that have used a fixed diagnostic cutoff for HCM. A fixed cutoff may have increased the inclusion of mild HCM in the healthy control group, especially if the cats were small, and extremely large cats may have been falsely included as mild HCM cats.

Conclusions

Analytical performance of the hs-cTnI analysis allows its clinical use in cats. There was an effect of both breed and sex on the serum concentration of cTnI. In cats with HCM, cTnI concentrations increased with increasing LV wall thickness, and cats with LAE had higher cTnI concentrations than cats with HCM without LAE and than healthy cats.

Supplemental Material

Supplement 1 Stability study

The concentration of cTnI decreased in serum samples stored at 20°C. After three days, the mean decrease was 4% in comparison with the initial value. Mean decrease was 14% after 5 days and 20% after 7 days (Supplement Figure 1). The cTnI concentration changed from -1 to 5% after three freeze-thaw cycles.

Supplemental Material

Supplement Table 1

Auscultation, basic echocardiographic and laboratory variables in 96 healthy Birman, Domestic Shorthair (DSH), and Norwegian Forest (NF) cats

Supplemental Material

Supplement Table 2

Auscultation, basic echocardiographic and laboratory variables in 96 healthy cats and 39 cats with hypertrophic cardiomyopathy (HCM)

Supplemental Material

Supplement Figure 1

The stability of cardiac troponin I (cTnI) concentration in serum samples from three cats with hypertrophic cardiomyopathy (HCM) after storage in the dark at 20°C

From cat one, two samples were studied (Cat 1a and Cat 1b).

Footnotes

Acknowledgements

The authors would like to thank the dedicated veterinary technicians at Evidensia Animal Clinic in Västerås for their important role in completing this study. Special thanks to all participating cats and their owners.

Accepted: 12 July 2022

Author note

This work was a part of Sofia Hanås’s PhD thesis. This paper was presented, in part, at the 31st ECVIM Online Congress as a short abstract and a poster in 2021.

Supplementary material

The following files are available online:

Supplementary Appendix 1: Stability study.

Supplementary Figure 1: The stability of cardiac troponin I concentration in serum samples from three cats with hypertrophic cardiomyopathy after storage in the dark at 20ºC.

Supplementary Table 1: Auscultation, basic echocardiographic and laboratory variables in 96 healthy Birman, domestic shorthair and Norwegian Forest Cats.

Supplementary Table 2: Auscultation, basic echocardiographic and laboratory variables in 96 healthy cats and 39 cats with hypertrophic cardiomyopathy.

Conflict of interest

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

This study was supported by the Foundation Strömsholms Djursjukvård, Agria and Swedish Kennel Club’s Research Fund, SLU Companion Animals Research Fund, Sveland Research Fund, and Michael Forsgren Foundation.

Ethical approval

The work described in this manuscript involved the use of non-experimental (owned or unowned) animals. Established internationally recognised high standards (‘best practice’) of veterinary clinical care for the individual patient were always followed and/or this work involved the use of cadavers. Ethical approval from a committee was therefore not specifically required for publication in JFMS. Although not required, where ethical approval was still obtained, it is stated in the manuscript.

Informed consent

Informed consent (either verbal or written) was obtained from the owner or legal custodian of all animal(s) described in this work (non-experimental animals, including cadavers) for all procedure(s) undertaken (prospective studies). No animals or people are identifiable within this publication, and therefore additional informed consent for publication was not required.

ORCID iD

Sofia Hanås

Anders Larsson

Jens Häggström

Bodil S Holst

References

Langhorn

Willesen

Tarnow

, et al. Evaluation of a high-sensitivity assay for measurement of canine and feline serum cardiac troponin I. Vet Clin Path 2013; 42: 490–498.

Hertzsch

Roos

Wess

. Evaluation of a sensitive cardiac troponin I assay as a screening test for the diagnosis of hypertrophic cardiomyopathy in cats. J Vet Intern Med 2019; 33: 1242–1250.

Hori

Iguchi

Heishima

, et al. Diagnostic utility of cardiac troponin I in cats with hypertrophic cardiomyopathy. J Vet Intern Med 2018; 32: 922–929.

Langhorn

Tarnow

Willesen

, et al. Cardiac troponin I and T as prognostic markers in cats with hypertrophic cardiomyopathy. J Vet Intern Med 2014; 28: 1485–1491.

Winter

Saunders

Gordon

, et al. Analytical validation and clinical evaluation of a commercially available high-sensitivity immunoassay for the measurement of troponin I in humans for use in dogs. J Vet Cardiol 2014; 16: 81–89.

Apple

Collinson

. Analytical characteristics of high-sensitivity cardiac troponin assays. Clin Chem 2012; 58: 54–61.

Apple

AHB

Sandoval

, et al. Sex-specific 99th percentile upper reference limits for high sensitivity cardiac troponin assays derived using a universal sample bank. Clin Chem 2020; 66: 434–444.

Clerico

Zaninotto

Ripoli

, et al. The 99th percentile of reference population for cTnI and cTnT assay: methodology, pathophysiology and clinical implications. Clin Chem Lab Med 2017; 55: 1634–1651.

Kimenai

Janssen

Eggers

, et al. Sex-specific versus overall clinical decision limits for cardiac troponin I and T for the diagnosis of acute myocardial infarction: a systematic review. Clin Chem 2018; 64: 1034–1043.

10.

Mueller

Egger

Peer

, et al. Evaluation of sex-specific cut-off values of high-sensitivity cardiac troponin I and T assays in an emergency department setting – results from the Linz Troponin (LITROP) study. Clin Chim Acta 2018; 487: 66–74.

11.

Love

Sandoval

Smith

, et al. Incidence of undetectable, measurable, and increased cardiac troponin I concentrations above the 99th percentile using a high-sensitivity vs a contemporary assay in patients presenting to the emergency department. Clin Chem 2016; 62: 1115–1119.

12.

LaVecchio

Marin

Baumwart

, et al. Serum cardiac troponin I concentration in retired racing greyhounds. J Vet Intern Med 2009; 23: 87–90.

13.

Baumwart

Orvalho

Meurs

. Evaluation of serum cardiac troponin I concentration in Boxers with arrhythmogenic right ventricular cardiomyopathy. Am J Vet Res 2007; 68: 524–528.

14.

Langhorn

Willesen

Tarnow

, et al. Cardiac troponin I in three cat breeds with hypertrophic cardiomyopathy. Vet Rec 2016; 178: 532. DOI: 10.1136/vr.103549.

15.

Serra

Papakonstantinou

Adamcova

, et al. Veterinary and toxicological applications for the detection of cardiac injury using cardiac troponin. Vet J 2010; 185: 50–57.

16.

Payne

Brodbelt

Luis Fuentes

. Cardiomyopathy prevalence in 780 apparently healthy cats in rehoming centres (the CatScan study). J Vet Cardiol 2015; 17 Suppl 1: S244–S257.

17.

Paige

Abbott

Elvinger

, et al. Prevalence of cardiomyopathy in apparently healthy cats. J Am Vet Med Assoc 2009; 234: 1398–1403.

18.

Luis Fuentes

Abbott

Chetboul

, et al. ACVIM consensus statement guidelines for the classification, diagnosis, and management of cardiomyopathies in cats. J Vet Intern Med 2020; 34: 1062–1077.

19.

Atkins

Gallo

Kurzman

, et al. Risk factors, clinical signs, and survival in cats with a clinical diagnosis of idiopathic hypertrophic cardiomyopathy: 74 cases (1985–1989). J Am Vet Med Assoc 1992; 201: 613–618.

20.

Rush

Freeman

Fenollosa

, et al. Population and survival characteristics of cats with hypertrophic cardiomyopathy: 260 cases (1990–1999). J Am Vet Med Assoc 2002; 220: 202–207.

21.

Payne

Borgeat

Connolly

, et al. Prognostic indicators in cats with hypertrophic cardiomyopathy. J Vet Intern Med 2013; 27: 1427.

22.

Herndon

Kittleson

Sanderson

, et al. Cardiac troponin I in feline hypertrophic cardiomyopathy. J Vet Intern Med 2002; 16: 558–564.

23.

Connolly

Cannata

Boswood

, et al. Cardiac troponin I in cats with hypertrophic cardiomyopathy. J Feline Med Surg 2003; 5: 209–216.

24.

Langhorn

Yrfelt

Stjernegaard

, et al. Analytical validation of a conventional cardiac troponin I assay for dogs and cats. Vet Clin Path 2019; 48: 36–41.

25.

Sangster

Panciera

Abbott

, et al. Cardiac biomarkers in hyperthyroid cats. J Vet Intern Med 2014; 28: 465–472.

26.

Bijsmans

Jepson

Wheeler

, et al. Plasma N-terminal probrain natriuretic peptide, vascular endothelial growth factor, and cardiac troponin I as novel biomarkers of hypertensive disease and target organ damage in cats. J Vet Intern Med 2017; 31: 650–660.

27.

Langhorn

Jessen

Kloster

, et al. Cardiac troponin I in cats with compromised renal function. J Feline Med Surg 2019; 21: 985–991.

28.

Sharpe

Gunther-Harrington

Epstein

, et al. Cats with thermal burn injuries from California wildfires show echocardiographic evidence of myocardial thickening and intracardiac thrombi. Sci Rep 2020; 10: 2648–2648.

29.

Hanås

Holst

Hoglund

, et al. Effect of feline characteristics on plasma N-terminal-prohormone B-type natriuretic peptide concentration and comparison of a point-of-care test and an ELISA test. J Vet Intern Med 2020; 34: 1187–1197.

30.

Hanås

Holst

Ljungvall

, et al. Influence of clinical setting and cat characteristics on indirectly measured blood pressure and pulse rate in healthy Birman, Norwegian Forest, and domestic shorthair cats. J Vet Intern Med 2021; 35: 801–811.

31.

Martel

Egner

Brown

, et al. Comparison of high-definition oscillometry – a non-invasive technology for arterial blood pressure measurement – with a direct invasive method using radio-telemetry in awake healthy cats. J Feline Med Surg 2013; 15: 1104–1113.

32.

Laflamme

. Development and validation of a body condition score system for cats: a clinical tool. Feline Pract 1997; 25: 13–18.

33.

Thomas

Gaber

Jacobs

, et al. Recommendations for standards in transthoracic two-dimensional echocardiography in the dog and cat. Echocardiography Committee of the Specialty of Cardiology, American College of Veterinary Internal Medicine. J Vet Intern Med 1993; 7: 247–252.

34.

Hansson

Haggstrom

Kvart

, et al. Left atrial to aortic root indices using two-dimensional and M-mode echocardiography in cavalier King Charles spaniels with and without left atrial enlargement. Vet Radiol Ultrasound 2002; 43: 568–575.

35.

Häggström

Andersson

Falk

, et al. Effect of body weight on echocardiographic measurements in 19,866 pure-bred cats with or without heart disease. J Vet Intern Med 2016; 30: 1601–1611.

36.

Sahn

DeMaria

Kisslo

, et al. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 1978; 58: 1072–1083.

37.

Wayne

. User verification of precision and estimation of bias; approved guideline. CLSI document EP15-A3. 3rd ed. Wayne, PA: CLSI, 2014.

38.

R Core Team.

R: a language and environment for statistical computing.

Vienna: R Foundation for Statistical Computing, 2020.

39.

Giannitsis

Mueller-Hennessen

Zeller

, et al. Gender-specific reference values for high-sensitivity cardiac troponin T and I in well-phenotyped healthy individuals and validity of high-sensitivity assay designation. Clin Biochem 2020; 78: 18–24.

40.

Clerico

Ripoli

Masotti

, et al. Evaluation of 99th percentile and reference change values of a high-sensitivity cTnI method: a multicenter study. Clin Chim Acta 2019; 493: 156–161.

41.

Venge

Johnston

Lagerqvist

, et al. Clinical and analytical performance of the liaison cardiac troponin I assay in unstable coronary artery disease, and the impact of age on the definition of reference limits. A FRISC-II substudy. Clin Chem 2003; 49: 880–886.

42.

Oyama

Sisson

. Cardiac troponin-I concentration in dogs with cardiac disease. J Vet Intern Med 2004; 18: 831–839.

43.

Ljungvall

Höglund

Tidholm

, et al. Cardiac troponin I is associated with severity of myxomatous mitral valve disease, age, and C-reactive protein in dogs. J Vet Intern Med 2010; 24: 153–159.

44.

Quimby

Smith

Lunn

. Evaluation of the effects of hospital visit stress on physiologic parameters in the cat. J Feline Med Surg 2011; 13: 733–737.

45.

Belew

Barlett

Brown

. Evaluation of the white-coat effect in cats. J Vet Intern Med 1999; 13: 134–142.

46.

Heinonen

Kalliokoski

Hannukainen

, et al. Organ-specific physiological responses to acute physical exercise and long-term training in humans. Physiol J 2014; 29: 421–436.

47.

Nie

Tong

Shi

, et al. Serum cardiac troponin response in adolescents playing basketball. Int J Sports Med 2008; 29: 449–452.

48.

Pourmohammad

Mohri

Seifi

, et al. Evaluation of cardiac troponin I, atrial natriuretic peptide and some oxidative/antioxidative biomarkers in the serum and hemolysate of trained Arabian horses after exercise. Iran J Vet Res 2020; 21: 211–215.

49.

Rossi

Kavsak

Maxie

, et al. Post-exercise cardiac troponin I release and clearance in normal Standardbred racehorses. Equine Vet J 2019; 51: 97–101.

50.

Nostell

Häggström

. Resting concentrations of cardiac troponin I in fit horses and effect of racing. J Vet Cardiol 2008; 10: 105–109.

51.

Gresslien

Agewall

. Troponin and exercise. Int J Cardiol 2016; 221: 609–621.

52.

Stavroulakis

George

. Exercise-induced release of troponin. Clin Cardiol 2020; 43: 872–881.

53.

Kubo

Kitaoka

Okawa

, et al. Combined measurements of cardiac troponin I and brain natriuretic peptide are useful for predicting adverse outcomes in hypertrophic cardiomyopathy. Circ J 2011; 75: 919–926.

54.

Borgeat

Sherwood

Payne

, et al. Plasma cardiac troponin I concentration and cardiac death in cats with hypertrophic cardiomyopathy. J Vet Intern Med 2014; 28: 1731–1737.

55.

Fox

Liu

Maron

. Echocardiographic assessment of spontaneously occurring feline hypertrophic cardiomyopathy. An animal model of human disease. Circulation 1995; 92: 2645–2651.

56.

Klues

Schiffers

Maron

. Phenotypic spectrum and patterns of left ventricular hypertrophy in hypertrophic cardiomyopathy: morphologic observations and significance as assessed by two-dimensional echocardiography in 600 patients. J Am Coll Cardiol 1995; 26: 1699–1708.

57.

Maron

McKenna

Danielson

, et al. American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol 2003; 42: 1687–1713.

58.

Häggstrom

Luis Fuentes

Wess

. Screening for hypertrophic cardiomyopathy in cats. J Vet Cardiol 2015; 17 Suppl 1: S134–S149.

59.

Wagner

Fuentes

Payne

, et al. Comparison of auscultatory and echocardiographic findings in healthy adult cats. J Vet Cardiol 2010; 12: 171–182.

60.

Marz

Wilkie

Harrington

, et al. Familial cardiomyopathy in Norwegian Forest Cats. J Feline Med Surg 2015; 17: 681–691.

61.

Mottet

Amberger

Doherr

, et al. Echocardiographic parameters in healthy young adult Sphynx cats. Schweiz Arch Tierheilkd 2012; 154: 75–80.

62.

Scansen

Morgan

. Reference intervals and allometric scaling of echocardiographic measurements in Bengal cats. J Vet Cardiol 2015; 17 Suppl 1: S282–S295.

63.

Schober

Savino

Yildiz

. Reference intervals and allometric scaling of two-dimensional echocardiographic measurements in 150 healthy cats. J Vet Med Sci 2017; 79: 1764–1771.

64.

Schober

Zientek

, et al. Effect of treatment with atenolol on 5-year survival in cats with preclinical (asymptomatic) hypertrophic cardiomyopathy. J Vet Cardiol 2013; 15: 93–104.

65.

Payne

Borgeat

Brodbelt

, et al. Risk factors associated with sudden death vs. congestive heart failure or arterial thromboembolism in cats with hypertrophic cardiomyopathy. J Vet Cardiol 2015; 17 Suppl 1: S318–S328.

66.

Payne

Fuentes

Boswood

, et al. Population characteristics and survival in 127 referred cats with hypertrophic cardiomyopathy (1997 to 2005). J Small Anim Pract 2010; 51: 540–547.

67.

Ironside

Tricklebank

Boswood

. Risk indictors in cats with preclinical hypertrophic cardiomyopathy: a prospective cohort study. J Feline Med Surg 2021; 23: 149–159.

68.

Maron

Olivotto

Maron

, et al. The case for myocardial ischemia in hypertrophic cardiomyopathy. J Am Coll Cardiol 2009; 54: 866–875.

69.

Falk

Ljungvall

Zois

, et al. Cardiac troponin-I concentration, myocardial arteriosclerosis, and fibrosis in dogs with congestive heart failure because of myxomatous mitral valve disease. J Vet Intern Med 2013; 27: 500–506.

70.

Krintus

Kozinski

Boudry

, et al. European multicenter analytical evaluation of the Abbott ARCHITECT STAT high sensitive troponin I immunoassay. Clin Chem Lab Med 2014; 52: 1657–1665.

71.

Egger

Dieplinger

Mueller

. One-year in vitro stability of cardiac troponins and galectin-3 in different sample types. Clin Chim Acta 2018; 476: 117–122.

72.

Klüser

Maier

Wess

. Evaluation of a high-sensitivity cardiac troponin I assay compared to a first-generation cardiac troponin I assay in Doberman Pinschers with and without dilated cardiomyopathy. J Vet Intern Med 2019; 33: 54–63.

73.

Usher-Smith

Sharp

Griffin

. The spectrum effect in tests for risk prediction, screening, and diagnosis. BMJ 2016; 353: i3139. DOI: 10.1136/bmj.i3139.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.02 MB

0.59 MB